Bangalore Bioinnovation Centre (BBC) is proud to announce that Pandorum Technologies, a BBC-incubated regenerative medicine startup, has raised $18 million (approximately ₹150 crore) in its Series B funding round.
The round was led by Protons Corporate, with significant participation from Galentic Pharma (India) Pvt. Ltd., Ashish Kacholia, Noblevast Advisory, Avinya Fund, and other prominent investors. This fresh capital marks a pivotal milestone for Pandorum as it prepares to scale its ground-breaking programmable tissue technologies on a global stage.
Advancing Regenerative Medicine Across Global Markets
The newly raised capital will enable Pandorum Technologies to:
- Push Clinical Programs Forward: Accelerate the development of its proprietary regenerative therapies through critical clinical trial phases.
- Scale Manufacturing: Enhance its production capabilities for lab-grown tissues and exosome-based therapies to meet global demand.
- Expand Market Access: Establish a stronger presence in high-impact markets, including the US, Japan, and the Middle East, while strengthening regulatory and clinical infrastructure.
Through these strategic efforts, Pandorum aims to bridge the gap between experimental biotechnology and real-world therapeutic applications, bringing life-changing treatments to patients worldwide.
Programmable Therapies: The Future of Biopharma
At the core of Pandorum's innovation is its focus on regenerative medicine, where it builds:
- Exosome-Based Therapies: Developing programmable, cell-free treatments designed to trigger natural healing processes in the body.
- Lab-Grown Tissues: Creating sophisticated biological scaffolds for drug discovery and therapeutic applications, reducing the reliance on traditional animal testing and donor transplants.
The company's mission is to "sculpt" biological functions, providing precise, bio-engineered solutions for chronic diseases and organ damage.
Investor Confidence in Deep Biotech
The round, which values the company at approximately $91 million post-money, reflects strong investor confidence in Pandorum's long-term vision. Lead investor Protons Corporate, along with partners like Galentic Pharma and Ashish Kacholia, recognize the immense potential of Pandorum's deep-tech platform to redefine modern healthcare.
Despite being in a pre-revenue stage—typical of the long gestation cycles in deep biotech—the company has now raised a total of $43 million to date, underscoring the high stakes and high rewards associated with regenerative innovation.
From Incubation to Global Leadership
Founded by Arun Chandru and Tuhin Bhowmick, Bengaluru-based Pandorum Technologies has spent years perfecting its platform within the Bangalore Bioinnovation Centre ecosystem. As a BBC-incubated startup, Pandorum has leveraged the Centre's world-class infrastructure, mentorship, and strategic network to transition from a research-focused entity to a globally recognized biotech leader.
Strengthening the Bioinnovation Frontier
The success of Pandorum Technologies further highlights the strength of the life sciences ecosystem in Karnataka. It serves as a testament to the power of collaboration between visionary entrepreneurs, bold investors, and state-of-the-art incubation facilities like the BBC.
BBC congratulates the entire Pandorum Technologies team on this remarkable Series B milestone and wishes them continued success as they advance their mission to transform the landscape of regenerative medicine globally.
